Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England.
While Western pharmaceutical companies struggle to enforce their IP rights in India, Roche has taken an unorthodox but surprisingly effective stance, as Debashish Banerjee and Shukadev Khuraijam explain.
A new referral to the CJEU should shed light on the extent of the so-called Bolar exemption in Europe, says Bernd Allekotte.
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.
Several of the world’s 10 top-selling drugs lose exclusivity this year. LSIPR takes a look at the products, their major competitors, and their manufacturers’ strategies for keeping a grasp of market share.
An individual gene profile provides a window into a person’s medical future, by examining DNA samples, but what are the best ways of regulating this developing technology? LSIPR looks at the challenges and possible solutions.
The US Supreme Court has again reversed a Federal Circuit decision, this time over burden of proof, says Matthew Nielsen.
The CJEU has delivered its judgment in three SPC cases, in an attempt to address fundamental issues in the SPC Regulation, as well as uncertainties arising from earlier rulings. Although questions have been answered, others have been raised, say David Carling and Michael Pears.
The Indian Supreme Court has failed to provide the clarity which is craved by practitioners in its latest pronouncement on the controversial Section 3(d), says Jitesh Kumar.
Common themes, in particular in the context of second medical use claims and dosage regimes, are on the radar of the UK courts, as Jennifer Antcliff and Dennis Waller report.